Bayer CropScience (506285) Q1 25/26 earnings summary

Executive summary

• Presented a five-year framework focused on sales, margin, and cash to drive long-term leadership and resilience.

• Emphasized innovation in seeds, traits, and crop protection as key growth drivers, with a robust pipeline of blockbuster products.

• Outlined a holistic approach to margin and cash improvement, including portfolio optimization, R&D focus, and operational efficiency.

• Highlighted global market leadership in corn and soy, with strategies to regain and expand market share.

• Addressed market cyclicality and external pressures, with measures to enhance resilience and adaptability.

Financial highlights

• Targeting above-market net sales growth, aiming for over EUR 25 billion by 2029.

• EBITDA margin expected to reach mid-20s by 2029, with 100–150 basis points annual expansion.

• More than EUR 1 billion improvement in clean EBITDA and over EUR 1.5 billion cumulative cash freed from working capital by 2029.

• Innovation pipeline expected to deliver over EUR 3.5 billion in incremental sales by 2029.

• Free operating cash flow projected to exceed EUR 3 billion by 2029.

Outlook and guidance

• Market growth assumed at 2% CAGR through 2029, with seeds and traits outpacing crop protection.

• Regulatory headwinds in crop protection expected to impact 2025–2026, but not recurring at the same scale.

• Blockbuster innovations to drive sustained growth beyond 2030.

• Margin and cash initiatives are under management control, supporting confidence in targets.